Identification of a novel tumor angiogenesis inhibitor targeting Shh/Gli1 signaling pathway in Non-small cell lung cancer

摘要

Pristimerin suppresses cell proliferation of HUVECs and HMEC-1 cells in a dose-dependent manner. The cells were treated with various concentration of pristimerin for 48 h, and the cell viability was detected using CCK-8 assay. Pristimerin treatment reduced Shh-induced cell viabilities of HUVECs and HMEC-1 cells. After starving with serum-free medium, the cells were treated with or without Shh (100 ng/mL) and various concentrations of pristimerin (125, 250, and 500 nM) for 48 h, and the cell viability was detected using CCK-8 assay. Pristimerin restrains Shh-induced horizontal migration of HUVECs and HMEC-1 cells. After being starved with non-serum ECM, the wound was generated with pipette tips in the monolayers of HUVECs and HMEC-1. And the cells were exposed to Shh and different concentrations of pristimerin for 10 h. And the images were photographed at 0 and 10 h. Representative images were shown and the quantification of migrated cells was presented at the right panel. Scale bar: 100 μm. , Pristimerin restrains Shh-induced migration and invasion of endothelial cells. The cells were seeded in the upper chamber of transwell that have pre-coated with or without Matrigel, and then the cells were exposed to Shh (100 ng/mL) and various concentrations of pristimerin for 24 h. After removing the cells in the inner of upper chamber, the migrated cells and invaded cells were photographed. And the representative images of migrated cells and invaded cells were presented in , , respectively. Scale bar: 100 μm. The data are presented as mean ± SEM,  = 3.  #  ###